Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
作者： Mark J. Cziraky , Karol E. Watson , Robert L. Talbert
DOI: 10.18553/JMCP.2008.14.S8-A.1
关键词:
摘要: BACKGROUND: Most clinicians recognize the importance of reducinglow-density lipoprotein cholesterol (LDL-C) and, therefore, address thistherapeutic need to decrease …
sci-hub.se 参考文章(116)
W. Virgil Brown, Expert commentary: the safety of fibrates in lipid-lowering therapy. American Journal of Cardiology. ,vol. 99, ,(2007) , 10.1016/J.AMJCARD.2006.11.017
Scott L. Charland, Mark J. Cziraky, Ralph Quimbo, Richard H. Karas, William Insull, Michael Davidson, Eric J. Stanek, Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events Journal of Clinical Lipidology. ,vol. 2, pp. 343- 353 ,(2008) , 10.1016/J.JACL.2008.06.009
John R. Downs, Michael Clearfield, Stephen Weis, Edwin Whitney, Deborah R. Shapiro, Polly A. Beere, Alexandra Langendorfer, Evan A. Stein, William Kruyer, Antonio M. Gotto, Jr, for the AFCAPS/TexCAPS Research Group, Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels JAMA. ,vol. 279, pp. 1615- 1622 ,(1998) , 10.1001/JAMA.279.20.1615
Soma S. Nag, Gregory W. Daniel, Michael F. Bullano, Sachin Kamal-Bahl, Shiva G. Sajjan, Henry Hu, Charles Alexander, LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. Journal of Managed Care Pharmacy. ,vol. 13, pp. 652- ,(2007) , 10.18553/JMCP.2007.13.8.652
Christie M. Ballantyne, Michael H. Davidson, James McKenney, Laurence H. Keller, Daiva R. Bajorunas, Richard H. Karas, Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). American Journal of Cardiology. ,vol. 101, pp. 1428- 1436 ,(2008) , 10.1016/J.AMJCARD.2008.02.092
Scott M. Grundy, Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy Circulation. ,vol. 106, pp. 2526- 2529 ,(2002) , 10.1161/01.CIR.0000038419.53000.D6
Caron Melikian, T.Jeffrey White, Ann Vanderplas, Christopher M. Dezii, Eunice Chang, Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clinical Therapeutics. ,vol. 24, pp. 460- 467 ,(2002) , 10.1016/S0149-2918(02)85047-0
B. Greg Brown, Marian C. Cheung, Andrew C. Lee, Xue-Qiao Zhao, Alan Chait, Antioxidant Vitamins and Lipid Therapy: End of a Long Romance? Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 22, pp. 1535- 1546 ,(2002) , 10.1161/01.ATV.0000034706.24149.95
Brian Meissner, Michael Dickson, Judy Shinogle, C. E. Reeder, Dea Belazi, Viran Senevirante, Drug and Medical Cost Effects of a Drug Formulary Change With Therapeutic Interchange for Statin Drugs in a Multistate Managed Medicaid Organization Journal of Managed Care Pharmacy. ,vol. 12, pp. 331- 340 ,(2006) , 10.18553/JMCP.2006.12.4.331
John C LaRosa, Scott M Grundy, David D Waters, Charles Shear, Philip Barter, Jean-Charles Fruchart, Antonio M Gotto, Heiner Greten, John JP Kastelein, James Shepherd, Nanette K Wenger, None, Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine. ,vol. 352, pp. 1425- 1435 ,(2005) , 10.1056/NEJMOA050461